Publicaciones en colaboración con investigadores/as de Royal Marsden Hospital (7)

2019

  1. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

    The Lancet Oncology, Vol. 20, Núm. 8, pp. 1109-1123

2014

  1. Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis

    Lung Cancer, Vol. 85, Núm. 2, pp. 230-238

2008

  1. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: Results of the international expanded access program

    Journal of Thoracic Oncology, Vol. 3, Núm. 7, pp. 756-763

  2. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

    British Journal of Cancer, Vol. 98, Núm. 10, pp. 1608-1613

2005

  1. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial

    Clinical Cancer Research, Vol. 11, Núm. 2 I, pp. 690-696

1994

  1. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

    Journal of Clinical Oncology, Vol. 12, Núm. 4, pp. 759-763

  2. High-dose melphalan for multiple myeloma: Long-term follow-up data

    Journal of Clinical Oncology, Vol. 12, Núm. 4, pp. 764-768